Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that heterozygous carriers of a mutation in the human hairless gene did not differ from healthy homozygotes in the pattern of androgenetic alopecia.

This review suggests that low-level light therapy can promote hair growth in patients with androgenetic alopecia, but more research is needed to standardize treatment parameters and assess long-term safety and efficacy.

Finasteride and minoxidil together safely and effectively increase hair growth and density for androgenetic alopecia.

This study observed that the genes WNT7A, CASP7, and TNF were overexpressed in early stages of androgenetic alopecia, suggesting involvement of the WNT pathway, apoptosis, and inflammation in the disorder's development.

This study found that men with androgenetic alopecia had significantly higher plasma leptin levels, which were associated with an increased risk of developing the condition.

This study found that plasma rich in growth factors was a safe and more effective treatment for androgenetic alopecia than topical minoxidil, showing greater improvements in hair growth phases.

This study found that trichoscopy is essential for evaluating the severity of alopecia areata and predicting treatment responses, contributing to more personalized patient management.

This study found that patients with androgenetic alopecia had increased oxidative stress and microinflammation, contributing to hair loss, due to elevated levels of specific serum biomarkers compared to controls.

LLLT is a safe, promising hair loss treatment, but more research needed.

This review discusses the role of androgen hormones in the pathophysiology of childhood androgenetic alopecia and reports no clinical results.

This study evaluated a new anti-baldness product, IPSTiC patch hair, designed to treat androgenetic alopecia, and reported that it effectively inhibits NO radical and 5α-reductase activity while maintaining safety and stability, suggesting its potential for topical use.

This study found that Italian dermatologists commonly prescribe 1 mg/day finasteride for androgenetic alopecia despite reported sexual side effects, due to its perceived long-term efficacy.

This research observed that finasteride-loaded ethosomes showed improved permeation across rat skin and human cadaver scalp skin compared to unencapsulated finasteride, potentially enhancing delivery to hair follicle units.

This study found that t-flavanone may promote hair growth in people with androgenic alopecia by enhancing hair anchoring strength and upregulating desmoglein expression in hair follicles over 30 weeks.

TR3 is mainly found in hair follicle stem cells and may be involved in hair loss.

This retrospective study found that treatment with autologous plasma rich in growth factors increased hair density and improved hair follicle health in patients with androgenetic alopecia, with no reported adverse effects.

This study found that specific CYP19A1 gene SNPs were significantly associated with female pattern hair loss risk in a Chinese Han population.

This study found that ethanolic and petroleum ether extracts of Cuscuta reflexa, as well as an isolate from these extracts, improved hair growth and follicle characteristics in androgen-induced alopecia in rats.

This study reported that a subcutaneous injection formulation using PLGA microspheres to release finasteride stably achieved sustained monthly drug delivery without burst release in beagle dogs, with a dose of 16.8 mg identified as optimal for potential first-in-human trials.

This study demonstrated that caffeine, minoxidil, and the HIF-1α-stimulating agent deferiprone significantly enhanced dermal papilla cell proliferation in a 3D culture model, suggesting deferiprone as a potential alternative to minoxidil.

In this study, patients with androgenic alopecia who underwent 10 sessions of 1540-nm fractional erbium glass laser treatment over 5 months experienced significant improvements in hair density and thickness, with no major safety concerns reported.

In this study, researchers identified 32 differentially expressed genes involved in androgenetic alopecia, with down-regulated genes associated with Wnt and TGF-beta signaling and up-regulated genes linked to oxidative stress pathways.

This study describes an analytical technique combining field-enhanced sample stacking with dispersive liquid-liquid microextraction, offering improved sensitivity for detecting finasteride and its metabolite in urine samples from patients treated for androgenetic alopecia.

This study found that a new topical botanical lotion significantly increased hair density and improved quality of life in women with androgenetic alopecia over 24 weeks.

In this study, Korean women with female pattern hair loss who used a combination of topical 0.025% 17α-estradiol and 3% minoxidil saw significant increases in total hair count and hair caliber over six months.

This study found that the risk of urinary stone disease increased significantly in patients with severe androgenetic alopecia, and that testosterone deficiency was more frequent among these patients.

This article reviews treatment options for androgenetic alopecia, highlighting potential uses of plant materials, but reports no new clinical results.

This study found that women with androgenetic alopecia demonstrated higher androgen receptor gene expression compared to controls, with a correlation found between higher AR expression and fewer CAG repeats in the AR gene.

SA linked to mitochondrial issues and oxidative stress, while AGA involves disrupted hair growth genes.

This study found that topical fulvestrant did not significantly improve hair growth parameters in men and postmenopausal women with androgenetic alopecia, unlike minoxidil, which was more effective in men.